Phase 1 CT Clinical Trials
1,218 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 1,218 trials
Recruiting
Phase 1
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 1
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases (NIAID)12 enrolled10 locationsNCT06118515
Recruiting
Phase 1
MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)
HIV Infection
Merck Sharp & Dohme LLC28 enrolled2 locationsNCT07042945
Recruiting
Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
Palliative CareIntractable Pain
National Institute of Dental and Craniofacial Research (NIDCR)45 enrolled1 locationNCT00804154
Recruiting
Phase 1
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 1Phase 2
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 1Phase 2
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting
Phase 1Phase 2
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 1
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Locally Advanced Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8+1 more
National Cancer Institute (NCI)18 enrolled11 locationsNCT05411094
Recruiting
Phase 1Phase 2
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute35 enrolled1 locationNCT07214298
Recruiting
Phase 1
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Pancreatic Adenocarcinoma Non-resectable
Continuity Biosciences, LLC12 enrolled2 locationsNCT07481383
Recruiting
Phase 1Phase 2
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia
National Cancer Institute (NCI)84 enrolled4 locationsNCT06965114
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 1
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 1Phase 2
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Phase 1
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI)43 enrolled23 locationsNCT05687110
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 1
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.36 enrolled2 locationsNCT07478302
Recruiting
Phase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972